Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Debt (2017 - 2024)

Historic Non-Current Debt for United Therapeutics (UTHR) over the last 13 years, with Q2 2024 value amounting to $100.0 million.

  • United Therapeutics' Non-Current Debt fell 8750.0% to $100.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $100.0 million, marking a year-over-year decrease of 8750.0%. This contributed to the annual value of $300.0 million for FY2023, which is 6250.0% down from last year.
  • Per United Therapeutics' latest filing, its Non-Current Debt stood at $100.0 million for Q2 2024, which was down 8750.0% from $200.0 million recorded in Q1 2024.
  • United Therapeutics' 5-year Non-Current Debt high stood at $800.0 million for Q1 2020, and its period low was $100.0 million during Q2 2024.
  • Moreover, its 5-year median value for Non-Current Debt was $800.0 million (2020), whereas its average is $683.3 million.
  • In the last 5 years, United Therapeutics' Non-Current Debt surged by 3333.33% in 2020 and then crashed by 8750.0% in 2024.
  • United Therapeutics' Non-Current Debt (Quarter) stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then plummeted by 62.5% to $300.0 million in 2023, then plummeted by 66.67% to $100.0 million in 2024.
  • Its Non-Current Debt stands at $100.0 million for Q2 2024, versus $200.0 million for Q1 2024 and $300.0 million for Q4 2023.